Medical combination for treating nervous system diseases

A composition and drug technology, applied in the field of pharmacy, can solve the problems of affecting sleep, obvious gastrointestinal reactions, and high incidence of sexual dysfunction

Active Publication Date: 2010-05-12
SHENZHEN AUSA PHARM CO LTD +2
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because fluoxetine has defects such as significantly affecting sleep, increasing agitation, obvious gastrointestinal reactions, and high incidence of sexual dysfunction, fluoxetine is still in need of improvement as a commonly used drug for neurasthenia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical combination for treating nervous system diseases
  • Medical combination for treating nervous system diseases
  • Medical combination for treating nervous system diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] Example 1 Paroxetine-quetiapine compound tablets (1000 tablets) containing 5 mg of paroxetine and 25 mg of quetiapine were prepared.

[0085] Formula: Paroxetine 5g

[0086] Quetiapine 25g

[0087] Lactose 50g

[0088] Microcrystalline Cellulose 50g

[0089] Starch 10g

[0090] Sodium carboxymethyl starch 60g

[0091] Magnesium Stearate 1g

[0092] Preparation method: pulverize 5g of paroxetine, 25g of quetiapine, 50g of lactose, 50g of crystal cellulose and 10g of starch, mix them uniformly, make a soft material with 10% povidone ethanol solution, granulate, dry, and granulate , the granules with a water content of about 3% are uniformly mixed with magnesium stearate, and compressed into tablets by a tablet machine. Each of the prepared compound tablets contains 5 mg of paroxetine and 25 mg of quetiapine, in a mass ratio of 1:5.

Embodiment 2

[0093] Example 2 Paroxetine-quetiapine compound tablets (1000 tablets) containing 10 mg of paroxetine and 100 mg of quetiapine were prepared.

[0094] Formula: Paroxetine 10g

[0095] Quetiapine 100g

[0096] Lactose 50g

[0097] Microcrystalline Cellulose 50g

[0098] Starch 10g

[0099] Sodium carboxymethyl starch 100g

[0100] Magnesium Stearate 1g

[0101] Preparation method: as in the preparation method of Example 1, each of the prepared compound tablets contains 10 mg of paroxetine and 100 mg of quetiapine, and the mass ratio is 1:10.

Embodiment 3

[0102] Example 3 Paroxetine-quetiapine compound tablets (1000 tablets) containing 10 mg of paroxetine and 400 mg of quetiapine were prepared.

[0103] Formula: Paroxetine 10g

[0104] Quetiapine 400g

[0105] Lactose 80g

[0106] Microcrystalline Cellulose 80g

[0107] Starch 10g

[0108] Sodium carboxymethyl starch 60g

[0109] Magnesium Stearate 1g

[0110] Preparation method: as in the preparation method of Example 1, each of the prepared compound tablets contains 10 mg of paroxetine and 400 mg of quetiapine, and the mass ratio thereof is 1:40.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicinal component to treat nervous system disease and usage in preparing the medicine of depression and neurasthenia, which is characterized by the following: building up the component with medicinal active element, medicinal carrier or shaped agent; building up the medicinal active element with selective serotonin reuptake depressant and quinoa sulfur flat; choosing the selective serotonin reuptake depressant from fustian, Palestine, seatplane, S-seatplane, sheplin and fufsammin; merging the selective serotonin reuptake depressant and quinoa sulfur flat; playing the role of 5-HT1A blocking-up action; decreasing adverse effect of the drug.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating nervous system diseases and its use in the preparation of medicines for treating depression or neurasthenia. The pharmaceutical composition is composed of pharmaceutical active ingredients and pharmaceutically acceptable carriers or excipients, wherein the pharmaceutical active ingredients are composed of Selective serotonin reuptake inhibitor and quetiapine composition. The present invention belongs to the field of pharmacy. Background technique [0002] Selective serotonin reuptake inhibitors (selective serotonin reuptake inhibitors, SSRIs) increase the production of 5-HT at the synaptic cleft by selectively inhibiting the reuptake of 5-HT by the presynaptic membrane of the central nervous system. It is clinically used in the treatment of depression, schizophrenia, panic attack and obsessive-compulsive disorder. Currently, SSRIs include fluoxetine, paroxetine, citalopram, sertralin,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/554A61K31/138A61K31/4525A61K31/343A61K31/136A61K31/15A61P25/00A61P25/24
Inventor 刘平王玉张轶菁龙海珍于多李华戴成祥张凤琴李劲彤徐希平
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products